Some takeawaysBeyond the bullets below, two key elements of interest to me include:
1. The completion of the $40M DND contract's Phase 2 (in Apr '23?)
2. Anticipated spin-off of the Health Division (Medicall and Imagine Health) in the coming year
Other key points:
- Revs. With 2021 having been in the middle of the pandemic and, accordingly, generated most C-19 related income (Revs 49M), I prefer comparing 2022 financials to those of 2020 - and come 2023 revs these should be compared to 2019, essentially contexts where C-19's not present. In that context, given that 2022 revs are $30.5M compared to 2020 revs of $12M, I think we're doing fine;
- Adj EBITDA. As highlighted above, it was normal to see exceptionally high Adj EBITDA of $15M for 2021. In that context a 2022 Adj EBITDA of $-1.6M fairs quite well against a 2020 Adj EBITDA of $-5M.
- Cash position. 2022 cash is $8M compared to 2020 $2M. This is very good given 2022 acquisitions and share buyback (NCIB), the latter having cost $2.4M for 21.6M shares
- Profits/Loss. While at first glance the reported loss is unfortunate, DM clarifies the fact that this loss is "...not a result of operations, but rather attributed to the expenses related to the acquisition, a decrease in the share price of the invested companies, and from non-cash expenses such as amortization, depreciation, and impairment of intangible assets."
- COVID-19 has come to an end. All DM COVID operations have come to an end, including all consolidations of operations and personnel as of April 10th, 2023.
- $40M DND contract. VERY POSITIVELY, Nexalogy is pleased to announce it has completed the second phase of the $40 million AI project aimed at aiding Canadian cyber security initiatives. It remains unclear as to when the 2nd phase was completed but, worst case, it was in Apr, meaning that income should be reported in Q2. We'll hopefully find out more during the conference call with, perhaps, some hint as to income generated...
- Medicall. While I would have liked to see a more substantial number of subscriptions by now, I remain confident that they're on the right track, especially given the frustrations surrounding access challenges to the health network, throughout Canada. Small steps will lead to leaps and bounds.
- Imagine Health. Technically IH should start generating $0.5K+/Q as of Q1 2023 and build on this over the coming months and years.
- dmEVS. Not unlike Medical, dmEVS remains a work in progress but I'm confident it will progressively generate increased income throughout 2023, with more meaningful income materializing from 2024 onwards.
- Datametrex Healthcare Division Spinoff - Medi-Call and Imagine Health Centres. In my opinion this is great news! Management plans to launch this development within the next 12 months, delivering enhanced value to stakeholders and customers alike.